The impact of an AIDS vaccine in developing countries: A new model and initial results

被引:32
作者
Stover, John [1 ]
Bollinger, Lori
Hecht, Robert
Williams, Clara
Roca, Eva
机构
[1] Futures Inst, Glastonbury, CT 06033 USA
[2] AIDS Vaccine Initiat, New York, NY USA
关键词
D O I
10.1377/hlthaff.26.4.1147
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
A new model was developed to examine the potential impacts of an AIDS vaccine in developing countries. The findings suggest that even a modestly efficacious first generation vaccine could have a profound effect on the AIDS pandemic. A vaccine with 50 percent efficacy provided to 30 percent of the population would reduce new annual infections by 34 percent (seventeen million infections avoided) over fifteen years and result in substantial financial savings. A more efficacious vaccine, combined with expanded delivery, would do even more to control the pandemic. It therefore makes sense to continue investing in AIDS vaccine research and development and the eventual manufacture and widespread distribution of a vaccine.
引用
收藏
页码:1147 / 1158
页数:12
相关论文
共 16 条
[1]   Potential public health impact of imperfect HIV type 1 Vaccines [J].
Anderson, R ;
Hanson, M .
JOURNAL OF INFECTIOUS DISEASES, 2005, 191 :S85-S96
[2]   Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 trial [J].
Auvert, B ;
Taljaard, D ;
Lagarde, E ;
Sobngwi-Tambekou, J ;
Sitta, M ;
Puren, A .
PLOS MEDICINE, 2005, 2 (11) :1112-1122
[3]   Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial [J].
Bailey, Robert C. ;
Moses, Stephen ;
Parker, Corette B. ;
Agot, Kawango ;
Maclean, Ian ;
Krieger, John N. ;
Williams, Carolyn F. M. ;
Campbell, Richard T. ;
Ninya-Achola, Jeckoniah O. .
LANCET, 2007, 369 (9562) :643-656
[4]  
Blower S., 2003, AIDS Reviews, V5, P113
[5]   Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus [J].
Davenport, MP ;
Ribeiro, RM ;
Chao, DL ;
Perelson, AS .
JOURNAL OF VIROLOGY, 2004, 78 (20) :11340-11351
[6]   What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: Issues involving surrogate end points in phase 3 trials [J].
Gilbert, PB ;
DeGruttola, VG ;
Hudgens, MG ;
Self, SG ;
Hammer, SM ;
Corey, L .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (02) :179-193
[7]   Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial [J].
Gray, Ronald H. ;
Kigozi, Godfrey ;
Serwadda, David ;
Makumbi, Frederick ;
Watya, Stephen ;
Nalugoda, Fred ;
Kiwanuka, Noah ;
Moulton, Lawrence H. ;
Chaudhary, Mohammad A. ;
Chen, Michael Z. ;
Sewankambo, Nelson K. ;
Wabwire-Mangen, Fred ;
Bacon, Melanie C. ;
Williams, Carolyn F. M. ;
Opendi, Pius ;
Reynolds, Steven J. ;
Laeyendecker, Oliver ;
Quinn, Thomas C. ;
Wawer, Maria J. .
LANCET, 2007, 369 (9562) :657-666
[8]  
Hecht R, 2006, PLOS MED, V3, P1992, DOI [10.1371/journal.pmed.0040455, 10.1371/journal.pmed.0030455]
[9]  
*JOINT UN PROGR HI, 2006, REP GLOB AIDS EP
[10]   Viral load and heterosexual transmission of human immunodeficiency virus type 1 [J].
Quinn, TC ;
Wawer, MJ ;
Sewankambo, N ;
Serwadda, D ;
Li, CJ ;
Wabwire-Mangen, F ;
Meehan, MO ;
Lutalo, T ;
Gray, RH .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (13) :921-929